Outcomes of immune tolerance induction with rituximab to eradicate high-titer inhibitor of hemophilia A: depicted by exponential decay model and the gene expression profile of different outcomes by RNA-sequencing
Journal of Thrombosis and Haemostasis · 2025
DOI: 10.1016/j.jtha.2025.04.015 ↗Kurz gefasst
Klinische Studie (Phase IV) in der Zeitschrift Journal of Thrombosis and Haemostasis, 2025. Verfasst von Zekun Li und 14 weiteren Autor:innen. Beteiligte Einrichtung: Hemophilia Comprehensive Care Center, Hematology Department, Beijing Children's Hospital, Capital Medical University, National Center for Children's …. Hauptthemen laut MEDLINE: Factor VIII, Hemophilia A, Immune Tolerance, Rituximab. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 61 Literaturangaben. Gefördert von: Capital Foundation of Medical Research and Development, National Natural Science Foundation of China, Beijing Municipal Science and Technology Commission.
Abstract (Originalsprache)
BACKGROUND: Eradication of inhibitors is still a desirable goal for patients with hemophilia A inhibitors. Combining rituximab with immune tolerance induction (ITI) is the secondline regimen, but data and predictors are limited. OBJECTIVES: To evaluate the efficacy of ITI-rituximab and to identify the predictors of prognosis. METHODS: In total, 76 children with high-titer inhibitor prospectively using low-dose ITI together with 1-3 round(s) of rituximab were evaluated for outcomes: success or failure and rapidity (rapid or slow) of inhibitor negativity (ie, inhibitor titers turned negative, inhibitor negativity [IN]). The whole-transcriptome RNA-sequencing (RNA-seq) was used to analyze the gene expression profile of 4 failure patients (excluding F8 large deletion) and 4 rapid success-IN patients. RESULTS: Success IN was achieved in 41 of 76 (53.9%) patients after first-round of rituximab, 50 of 76 (65.8%) after second-round of rituximab, and 51 of 76 (67.1%) after third-round of rituximab. Profile of inhibitor decay followed an exponential decay curve. Time to a given inhibitor titer during ITI-rituximab could be estimated by the model t=ln(Y0-PlateauY-Plateau)k. The newly observed poor prognostic factors included relapse after the first-round of rituximab and early occurence of poor-outcome events. RNA-seq analysis showed 186 upregulated differential expressed genes (DEGs) and 176 downregulated DEGs in failure subjects compared with those in patients with rapid success IN. The upregulated DEGs included CXCL8, NLRP6, CHI3L1, CLEC9A, THBD, and PROS1. The downregulated DEGs included STAT1, TLR7, C1Q, C2, IDO1, and CD38. CONCLUSION: Success IN was achieved in 67% of children with hemophilia A with high-titer inhibitor treated by ITI-rituximab. A model based on the profile of inhibitor-titer decay can be used for predicting outcomes. Humoral immune response and complement and coagulation cascades may act as signals that influence ITI outcomes (ClinicalTrials.gov: NCT03598725).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hemophilia Comprehensive Care Center, Hematology Department, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
- State Key Laboratory of Multimodal Artificial Intelligence Systems, Institute of Automation, Chinese Academy of Sciences, Beijing, China.
- Hematologic Disease Laboratory, Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, Beijing, China.
- Department of Pharmacy, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
- Center for Clinical Epidemiology and Evidence-based Medicine, Capital Medical University, Beijing, China.
- Hemophilia Comprehensive Care Center, Hematology Department, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China; Pediatrics Departments, National Key Disciplin…
Förderung
- Capital Foundation of Medical Research and Development
- National Natural Science Foundation of China
- Beijing Municipal Science and Technology Commission
- Shanghai Jiao Tong University
- Natural Science Foundation of Beijing Municipality
- Beijing Children's Hospital, Capital Medical University
- National Key Research and Development Program of China
Zitieren
APA
Li, Z., Tang, Y., Chen, Z., Liu, G., Yao, W., Li, G., Cheng, X., Peng, Y., Cai, S., Cui, C., Ai, D., Zhang, J., Poon, M. C., Zhang, W., & Wu, R. (2025). Outcomes of immune tolerance induction with rituximab to eradicate high-titer inhibitor of hemophilia A: depicted by exponential decay model and the gene expression profile of different outcomes by RNA-sequencing. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2025.04.015
Vancouver
Li Z, Tang Y, Chen Z, Liu G, Yao W, Li G, et al. Outcomes of immune tolerance induction with rituximab to eradicate high-titer inhibitor of hemophilia A: depicted by exponential decay model and the gene expression profile of different outcomes by RNA-sequencing. Journal of Thrombosis and Haemostasis. 2025. doi:10.1016/j.jtha.2025.04.015
BibTeX
@article{Li2025,
author = {Li, Zekun and Tang, Yongqiang and Chen, Zhenping and Liu, Guoqing and Yao, Wanru and Li, Gang and Cheng, Xiaoling and Peng, Yaguang and Cai, Siyu and Cui, Chang and Ai, Di and Zhang, Jialu and Poon, Man Chiu and Zhang, Wensheng and Wu, Runhui},
title = {Outcomes of immune tolerance induction with rituximab to eradicate high-titer inhibitor of hemophilia A: depicted by exponential decay model and the gene expression profile of different outcomes by RNA-sequencing},
journal = {Journal of Thrombosis and Haemostasis},
year = {2025},
doi = {10.1016/j.jtha.2025.04.015}
}
EUVIMED